Zobrazeno 1 - 10 of 102 pro vyhledávání: '"V., Komrska"'
1
A Practical, One-Clinic Visit Protocol for Pharmacokinetic Profile Generation with the ADVATE myPKFiT Dosing Tool in Severe Hemophilia A Subjects
Autor: V. Komrska, Viviane Grassmann, Jan Blatny, Shannon Jackson, Derek Stephens, Massimo Morfini, Julie Curtin, Laura Zunino, Victor S. Blanchette, Ester Zapotocka, Manuel Carcao, Liane Khoo, Margaret L. Rand, Chris Barnes, Gabriela Romanova, David Lillicrap
Publikováno v: Thrombosis and Haemostasis
Standard pharmacokinetic (PK) assessments are demanding for persons with hemophilia A, requiring a 72-hour washout and 5 to 11 timed blood samples. A no-washout, single-clinic visit, sparse sampling population PK (PPK) protocol is an attractive alter
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b54c0b0ef4f9551ca6c85e3c356f3d5b
https://doi.org/10.1055/a-1376-0970
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Low incidence of factor VIII inhibitors in previously untreated patients with severe haemophilia A treated with octanate
Autor: A, Klukowska, V, Komrska, V, Vdovin, A, Pavlova, M, Jansen, S, Lowndes, L, Belyanskaya, O, Walter, P, Laguna
Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 24(2)
OctanateThis prospective, open-label study aimed to assess the immunogenicity of octanateThe study monitored development of FVIII inhibitors in 51 PUPs. Tolerability, viral safety, FVIII recovery and efficacy of octanateFive (9.8%) of the 51 patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d59552bc1120268469d830c4e313eaf8
https://pubmed.ncbi.nlm.nih.gov/29314439
Zobrazit plný text záznamu
4
[Pregnancy in women with congenital bleeding disorder]
Autor: T, Binder, P, Salaj, V, Komrska
Publikováno v: Ceska gynekologie. 81(6)
To highlight the risks associated with pregnancy at women with von Willebrand´s disease or hemophilia. Introduce the rules of multidisciplinary prenatal and peripartal care to minimalize these risks. The article is accompanied by case report where m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::220ea4af467d2445055b7d6ed5d33ffd
https://pubmed.ncbi.nlm.nih.gov/27918159
Zobrazit plný text záznamu
5
A Practical, One Clinic Visit, Population Pharmacokinetic (PK) Protocol for Generation of PK Profiles in Subjects with Severe Hemophilia a
Autor: Ester Zapotocka, Victor S. Blanchette, Laura Tiseo, David Lillicrap, Shannon Jackson, Jan Blatny, Liane Khoo, Massimo Morfini, Manuel Carcao, Vanessa Bouskill, V. Komrska, Margaret L. Rand, Derek Stephens
Publikováno v: Blood. 132:2480-2480
Introduction Clearance of infused factor VIII (FVIII) varies approximately 2-fold between persons with severe hemophilia A. This results in significant interpatient differences in factor levels following an infusion of FVIII and contributes to potent
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd305139b9afc02eff4dc4f262df3c38
https://doi.org/10.1182/blood-2018-99-111024
Zobrazit plný text záznamu
6
Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study
Autor: Anna Klukowska, V. Komrska, M. Jansen, Pawel Laguna
Publikováno v: Haemophilia. 17:399-406
For patients with haemophilia A (HA), lifelong replacement therapy with factor VIII (FVIII) concentrates is the treatment of choice. Octanate(®) is a plasma-derived, human, von Willebrand factor-stabilized FVIII product with demonstrated haemostatic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ff8a7a924b5e638bc1f6d1e556d9d76c
https://doi.org/10.1111/j.1365-2516.2010.02428.x
Zobrazit plný text záznamu
7
Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 2003
Autor: V. Komrska, Petra Ovesná, Miroslav Penka, Bohumir Blazek, Jan Blatny
Publikováno v: Blood coagulationfibrinolysis : an international journal in haemostasis and thrombosis. 26(6)
Our objective was to assess the incidence of inhibitors development in Czech Republic since the introduction of recombinant factor VIII (rFVIII) and to look for the factors potentially influencing this parameter. It is to be expected that inhibitors
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9bc21e1bf665add951a823b259a2ac0
https://pubmed.ncbi.nlm.nih.gov/25886834
Zobrazit plný text záznamu
10
Boys with haemophilia have low trabecular bone mineral density and sarcopenia, but normal bone strength at the radius
Autor: O, Soucek, V, Komrska, Z, Hlavka, O, Cinek, M, Rocek, D, Zemkova, J, Lebl, Z, Sumnik
Publikováno v: Haemophilia : the official journal of the World Federation of Hemophilia. 18(2)
Although a decreased areal bone mineral density (BMD) has been reported in patients with haemophilia, data are lacking that would reflect the three-dimensional structure of the bone and the muscle-bone relationship. We aimed to assess volumetric BMD,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1c4ad88aecf4a6dbfc99438cee5bb384
https://pubmed.ncbi.nlm.nih.gov/21752160
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje